# Anthony Chow

> Anthony Chow is a startup investor at Juvenescence (London). See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Juvenescence](https://shizune.co/investors/profile/juvenescence)
- Location: London, United Kingdom
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/anthony-chow-cfa-3a29b729

Anthony Chow is a CFA Charter holder with broad experience as an investor. He commenced his career at ANZ Banking Group Ltd in Sydney, Australia where he worked as an analyst for four years in the corporate banking, leveraged finance and private equity teams.In 2007, Anthony moved to London to work for Jim Mellon at Burnbrae Group and RegentPacific. Since joining, he was responsible research, direct investments, portfolio construction, risk management and facilitating trades in a wide range of financial instruments. He has worked closely with portfolio companies and respective coinvestors. He is currently the CEO of Burnbrae’s subsidiary Mann Bioinvest Limited and consultant to Juvenescence. He also sits on the board of The Diabetic Boot Company Limited, a medical device company.Anthony holds a Bachelor of Economics and Finance from The University of Sydney and a Post Graduate Diploma in Accounting from Macquarie University. He was awarded the CFA designation in 2010.

## About Juvenescence

VC Fund · Douglas, Isle of Man

Juvenescence Limited is a British Virgin Islands-based holding company that invests in human aging and longevity. Juvenescence has raised $111M to build an ecosystem and pipeline of assets targeting aging, age-related disease, and regeneration. Juvenescence believes that recent scientific and medical advances will enable the development oftherapeutics that meaningfully extend human healthspan and eventually lifespan. A meaningful increase in lifespan in the already aging world will have profound implications on all sectors of society, and in particular healthcare, education, insurance, and leisure.The company creates and partners with new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures with the foremost longevity scientists and leading research institutions. Their work is based on a novel scientific understanding of the underlying biological causes of aging, to create evidence-based therapeutics that can treat diseases of aging.Juvenescence's goal is to extend both lifespan and healthspan, by developing therapeutics that slow aging and promote juvenescence.

5 contacts available at Juvenescence.

| Name | Title | Profile |
| --- | --- | --- |
| Anthony Chow | VP IR | https://shizune.co/investors/profile/anthony-chow-297b |
| Jim Mellon | Chairman | https://shizune.co/investors/profile/jim-mellon |
| Alexander Pickett | Managing Director | https://shizune.co/investors/profile/alexander-pickett |
| Casey Swerner | Vice President | https://shizune.co/investors/profile/casey-swerner |
| Declan Doogan | Chief Medical Officer | https://shizune.co/investors/profile/declan-doogan |

## FAQ

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co